Literature DB >> 27166602

Blastic plasmacytoid dendritic cell neoplasm.

Naveen Pemmaraju1.   

Abstract

Entities:  

Mesh：

Year:  2016        PMID： 27166602

Source DB:  PubMed          Journal:  Clin Adv Hematol Oncol        ISSN： 1543-0790


× No keyword cloud information.
  10 in total

Review 1.  Social Media and Hematopoietic Cell Transplantation: a Review of Online Resources and Communities.

Authors:  Sagar S Patel; Navneet S Majhail
Journal:  Curr Hematol Malig Rep       Date:  2018-12       Impact factor: 3.952

Review 2.  Social Media and Internet Resources for Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN).

Authors:  Naveen Pemmaraju; Vikas Gupta; Michael A Thompson; Andrew A Lane
Journal:  Curr Hematol Malig Rep       Date:  2016-12       Impact factor: 3.952

Review 3.  Novel Pathways and Potential Therapeutic Strategies for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): CD123 and Beyond.

Authors:  Naveen Pemmaraju
Journal:  Curr Hematol Malig Rep       Date:  2017-12       Impact factor: 3.952

Review 4.  Tagraxofusp: First Global Approval.

Authors:  Yahiya Y Syed
Journal:  Drugs       Date:  2019-04       Impact factor: 9.546

5.  LXR agonist treatment of blastic plasmacytoid dendritic cell neoplasm restores cholesterol efflux and triggers apoptosis.

Authors:  Adam Ceroi; David Masson; Anne Roggy; Christophe Roumier; Cécile Chagué; Thierry Gauthier; Laure Philippe; Baptiste Lamarthée; Fanny Angelot-Delettre; Francis Bonnefoy; Sylvain Perruche; Sabeha Biichle; Claude Preudhomme; Elisabeth Macintyre; Laurent Lagrost; Francine Garnache-Ottou; Philippe Saas
Journal:  Blood       Date:  2016-10-04       Impact factor: 22.113

Review 6.  Analysis of First-Year Twitter Metrics of a Rare Disease Community for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) on Social Media: #BPDCN.

Authors:  Naveen Pemmaraju; Audun Utengen; Vikas Gupta; Michael A Thompson; Andrew A Lane
Journal:  Curr Hematol Malig Rep       Date:  2017-12       Impact factor: 3.952

Review 7.  Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) on Social Media: #BPDCN-Increasing Exposure over Two Years Since Inception of a Disease-Specific Twitter Community.

Authors:  Naveen Pemmaraju; Audun Utengen; Vikas Gupta; Michael A Thompson; Andrew A Lane
Journal:  Curr Hematol Malig Rep       Date:  2018-12       Impact factor: 3.952

8.  Blastic Plasmacytoid Dendritic Cell Neoplasm with Pulmonary Involvement and Atypical Skin Lesion.

Authors:  Cyndi Myrelle da Silva Barros Romão; Cláudio José Dos Santos Júnior; Luiz Arthur Calheiros Leite; Maria Jordana Rocha Gomes Alves; Nathalia Silva Araújo; Anderson F L Castro; Muriel Silva Moura; Vitória Mikaelly da Silva Gomes; Arthur Moacir Costa Sampaio Batinga; João Antonio S Queiroz; Natanael Barbosa Dos Santos
Journal:  Am J Case Rep       Date:  2017-06-21

Review 9.  Clinicopathologic retrospective analysis of blastic plasmacytoid dendritic cell neoplasms.

Authors:  Agnieszka Owczarczyk-Saczonek; Małgorzata Sokołowska-Wojdyło; Berenika Olszewska; Marta Malek; Aleksandra Znajewska-Pander; Anna Kowalczyk; Wojciech Biernat; Grażyna Poniatowska-Broniek; Wanda Knopińska-Posłuszny; Zygmunt Kozielec; Roman Nowicki; Waldemar Placek
Journal:  Postepy Dermatol Alergol       Date:  2018-04-24       Impact factor: 1.837

10.  Blastic plasmacytoid dendritic cell neoplasm: genomics mark epigenetic dysregulation as a primary therapeutic target.

Authors:  Maria Rosaria Sapienza; Francesco Abate; Federica Melle; Stefania Orecchioni; Fabio Fuligni; Maryam Etebari; Valentina Tabanelli; Maria Antonella Laginestra; Alessandro Pileri; Giovanna Motta; Maura Rossi; Claudio Agostinelli; Elena Sabattini; Nicola Pimpinelli; Mauro Truni; Brunangelo Falini; Lorenzo Cerroni; Giovanna Talarico; Rossana Piccioni; Stefano Amente; Valentina Indio; Giuseppe Tarantino; Francesco Brundu; Marco Paulli; Emilio Berti; Fabio Facchetti; Gaetano Ivan Dellino; Francesco Bertolini; Claudio Tripodo; Raul Rabadan; Stefano A Pileri
Journal:  Haematologica       Date:  2018-10-31       Impact factor: 9.941
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.